VAŠKŮ, Vladimír, Anna VAŠKŮ and Julie BIENERTOVÁ VAŠKŮ. Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma. International Journal of Clinical and Experimental Pathology, USA: e-Century Publishing Corporation, Madiso, 2009, 2/2009, No 2, p. 163-168. ISSN 1936-2625.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma
Name in Czech Farmakogenetický příspěvek polymorfismu v genu pro leptin u kožních T-lymfomů
Authors VAŠKŮ, Vladimír (203 Czech Republic, guarantor), Anna VAŠKŮ (203 Czech Republic) and Julie BIENERTOVÁ VAŠKŮ (203 Czech Republic).
Edition International Journal of Clinical and Experimental Pathology, USA, e-Century Publishing Corporation, Madiso, 2009, 1936-2625.
Other information
Original language English
Type of outcome Article in a journal
Field of Study Genetics and molecular biology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/09:00034200
Organization unit Faculty of Medicine
UT WoS 000208021800006
Keywords in English leptin; gene polymorphism; pharmacogenetics; cutaneous T-cell lymphoma
Tags cutaneous T-cell lymphoma, Gene polymorphism, leptin, Pharmacogenetics
Tags International impact, Reviewed
Changed by Changed by: prof. MUDr. Anna Vašků, CSc., učo 122. Changed: 18/6/2009 08:49.
Abstract
Abstract: Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.
Abstract (in Czech)
Abstract: Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.
PrintDisplayed: 25/11/2020 04:02